OCSAW Projected Dividend Yield

Wt Exp/Oculis Holding AG ( NASDAQ : OCSAW )

Oculis Holding is a clinical-stage biopharmaceutical company, engaged in the development of drug candidates to address eye-related conditions. Co.'s clinical portfolio includes: OCS-01, which is being evaluated for the treatment of diabetic macular edema and for the treatment of inflammation and pain following cataract surgery; OCS-02, which is a treatment for keratoconjunctivitis sicca, or dry eye disease and a treatment for non-infectious anterior uveitis; and OCS-05, which is a neuroprotective agent with potential application in multiple indications, including glaucoma, geographic atrophy, diabetic retinopathy and neurotrophic keratitis.

20 YEAR PERFORMANCE RESULTS